Reports Q2 revenue $181.4M, consensus $137.67M. Reports Q2 net loss $71.8M, including $37.1M of one-time expense associated with the conversion of redeemable convertible preferred stock, warrants and convertible notes from the initial public offering. “Our Q2 results show the strength of our comprehensive approach and we look forward to continuing to build on this momentum into the second half of 2025,” said David D. Halbert, Founder, Chairman and CEO of Caris Life Sciences (CAI).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Private Markets: Canva draws attention as IPO candidate following Figma debut
- Caris Life Sciences publishes new study on AI-based image analysis model
- TER, NVDA, AMD: Cathie Wood Makes Million-Dollar Bets on AI and Robotics
- ROKU, ACHR: Cathie Wood Offloads Millions in Roku and Archer Aviation Stocks
- Cathie Wood’s ARK Investment buys 52.5K shares of Caris Life Sciences today